In the liver, FXR deactivates hepatic lipogenesis by inhibiting SREBP1c, promotes FFA β‐oxidation by activating peroxisome proliferator‐activated receptor‐α (PPARα), and facilitates the clearance of VLDL in plasma by regulating microsomal triglyceride transfer protein (MTTP), ultimately improving metabolic dysfunction in MASLD.421, 422, 423. The gene discussed is MTTP; the disease is metabolic dysfunction-associated steatotic liver disease.